This program is supported by an independent education grant from Pfizer. This online education program has been designed for healthcare professionals globally.

In this virtual webinar, leading experts Dr Barry Laird, Dr Richard Dunne and Dr Eric Roeland explore practical, evidence-based strategies for the early recognition, assessment, and multidisciplinary management of cancer cachexia. Through interactive, case-based discussions, the faculty address real-world implementation challenges across oncology care settings—guiding clinicians on implementing standardized screening tools, integrating multimodal supportive care, and applying emerging science like GDF-15 biology to evaluate novel clinical trial opportunities for patients facing weight loss, muscle wasting, and functional decline.

Credits: 0.75 AMA PRA Category 1 Credits™ (0.75.00 hours)

Session Highlights

• Recognizing Cachexia Earlier: Standardizing screening, assessment, and documentation strategies to identify cancer cachexia at earlier stages in patients experiencing weight loss, muscle wasting, and functional impairment.
• Optimizing Multidisciplinary Supportive Care: Integrating evidence-based nutritional, rehabilitative, pharmacologic, and symptom-management approaches into patient care pathways.
• Translating Emerging Cachexia Science: Applying emerging data on GDF-15 biology and evolving targeted cachexia therapies when identifying and evaluating eligible patients for clinical trial opportunities.
• Real-World Practice & Implementation: Faculty-led interactive Q&A and clinical pearls focused on overcoming operational barriers and improving care delivery across diverse global oncology settings.

Who Should Watch

This program is designed for healthcare professionals involved in the diagnosis, treatment, supportive management, and longitudinal follow-up of people with cancer across oncology care settings:

• Medical Oncologists
• Oncology Nurses
• Nurse Practitioners
• Physician Associates/Assistants
• Pharmacists

Presented by

Dr Barry Laird is a Consultant in Palliative Medicine at the Edinburgh Cancer Centre and St Columba’s Hospice, as well as a leading investigator within the Edinburgh Palliative and Supportive Care Group at the Institute of Genetics and Cancer. His translational research program centers on the systemic inflammatory response in advanced cancer and its pivotal role in driving severe, debilitating symptoms such as cachexia, fatigue, pain, and functional decline. Collaborating closely across multidisciplinary academic teams, clinical networks, and industry partners, Dr. Laird bridges basic science and clinical trials to advance patient stratification, refine prognostication, and develop targeted therapeutic interventions that optimize quality of life for individuals living with cancer.

Dr Richard Dunne, MD, MS, is an Associate Professor in the Department of Medicine (Hematology/Oncology) at the University of Rochester Medical Center. Specializing in gastrointestinal and pancreatobiliary malignancies, his clinical practice and research focus extensively on pancreatobiliary cancers as well as cancer-associated weight loss and muscle wasting (cachexia). Supported by prominent funding—including the global Cancer Grand Challenges award dedicated to understanding and reversing cachexia—Dr. Dunne actively leads clinical trials evaluating novel cancer therapeutics. He is deeply committed to an empathetic, patient-centered approach, prioritizing open communication and shared decision-making to empower patients and their families throughout the treatment journey.

Dr Eric Roeland, MD, FASCO, FAAHPM, is an Associate Professor of Medicine in the Division of Hematology/Medical Oncology at the OHSU Knight Cancer Institute. Dual-certified in medical oncology and hospice and palliative medicine, his clinical practice centers on caring for patients with cutaneous and ocular cancers as well as managing complex, treatment-related symptoms. Dr. Roeland’s research focuses on symptom science—with specialized expertise in cancer cachexia, immunotherapy toxicities, and neuropathy—aimed at minimizing treatment side effects and optimizing quality of life across the cancer care continuum. He completed his medical degree at the University of Colorado, followed by residency and advanced fellowship training at UC San Diego and San Diego Hospice, and actively contributes to national and international supportive care organizations including ASCO, MASCC, and AAHPM.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Pfizer.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Richard Dunne has disclosed financial relationships within the past 24 months with the following ineligible companies: Eisai, Advisory Board; Incyte, Advisory Board.; Pfizer; Executive Steering Committee Member.

Barry Laird has disclosed financial relationships within the past 24 months with the following ineligible companies: Abbott, Artelo, Aveo Pharmaceuticals, Catalym, Pfizer. These relationships include Consultant.

Eric Roeland has disclosed financial relationships within the past 24 months with the following ineligible companies: Aveo Pharmaceuticals, Napo Pharmaceuticals, Pfizer. These relationships include Scientific Advisory Board, Research funding (to institution)

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

• When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
• Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

EBAC® CME Information:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

MedAll is an EBAC accredited provider since 2025. The European Board for Accreditation of Continuing Education for Health Professionals (EBAC) accredits Continuing Education (CE) programmes for the international medical community.

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.75 hour of effective education time.

In compliance with EBAC guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of participation in an activity eligible for conversion of credit to AMA PRA Category 1 Credit.

The Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

How to Obtain Your EBAC® CME Credit:

To obtain your CME credit and acquire your certificate, please join the webinar and complete the evaluation at the end. You will receive a link to your certificate after completing the evaluation.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting September 1st 2026 and will expire on September 1st 2026.

Estimated time to complete this activity: 45 minutes.